Skip to content

Released Mar 23, 2023, before the open

10-K filed Mar 23, 2023, 82 days after period end · 0001785530-23-000009

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$11.93MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$13,179,000N/M
Operating Cash Flowderived-$11,870,000N/M
Free Cash Flowderived-$12,388,000N/M

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Net Income-$11.93M-$17.87M-$7.40M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR